Performance of KYMR Kymera Therapeutics | 323.6% in 12m
Compare KYMR with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Kymera Therapeutics with its related Sector/Index XBI
Performance Duell KYMR vs XBI
| TimeFrame | KYMR | XBI |
|---|---|---|
| 1 Week | -0.53% | -3.57% |
| 1 Month | -2.44% | -2.54% |
| 3 Months | 12.1% | -3.08% |
| 6 Months | 36.5% | 14.30% |
| 12 Months | 323.6% | 46.30% |
| YTD | 92.4% | 7.29% |
| Rel. Perf. 1m | -0.37 | |
| Rel. Perf. 3m | 2.86 | |
| Rel. Perf. 6m | 1.64 | |
| Rel. Perf. 12m | 10.38 | |
| Spearman 1m | -0.05 | 0.261 |
| Spearman 3m | 0.39 | 0.027 |
Is Kymera Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Kymera Therapeutics (NASDAQ:KYMR) is currently (October 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -50.77 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KYMR as of October 2024 is 71.74. This means that KYMR is currently undervalued and has a potential upside of +47.13% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KYMR as of October 2024 is 71.74. This means that KYMR is currently undervalued and has a potential upside of +47.13% (Margin of Safety).
Is KYMR a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
Values above 0%: KYMR is performing better - Values below 0%: KYMR is underperforming
Compare KYMR with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 0.21% | -3.90% | 21.51% | 281.63% |
| US NASDAQ 100 | QQQ | -0.01% | -3.54% | 21.31% | 280.55% |
| US Dow Jones Industrial 30 | DIA | 0.73% | -3.44% | 25.19% | 291.63% |
| German DAX 40 | DAX | 0.61% | -1.82% | 29.90% | 290.32% |
| UK FTSE 100 | ISFU | 0.79% | 0.49% | 27.92% | 299.34% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -3.23% | -22.71% | 20.83% | 307.57% |
| Hongkong Hang Seng | HSI | 0.85% | -7.76% | 17.09% | 311.59% |
| India NIFTY 50 | INDA | 2.26% | 3.81% | 29.91% | 293.84% |
| Brasil Bovespa | EWZ | 1.02% | 0.94% | 43.68% | 325.37% |
KYMR Kymera Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 0.22% | -4.11% | 24.12% | 279.45% |
| Consumer Discretionary | XLY | 1.91% | -0.12% | 23.59% | 291.47% |
| Consumer Staples | XLP | 0.17% | -0.95% | 26.53% | 298.96% |
| Energy | XLE | -0.09% | -3.21% | 41.58% | 316.49% |
| Financial | XLF | 0.25% | -6.12% | 21.13% | 274.14% |
| Health Care | XLV | 1.35% | 0.15% | 29.28% | 301.66% |
| Industrial | XLI | 1.30% | -4.73% | 24.72% | 280.98% |
| Materials | XLB | 0.87% | -3.77% | 27.10% | 293.41% |
| Real Estate | XLRE | 0.36% | -1.24% | 13.02% | 284.07% |
| Technology | XLK | -0.11% | -5.29% | 20.25% | 279.97% |
| Utilities | XLU | -0.42% | -4.67% | 10.91% | 281.93% |
| Aerospace & Defense | XAR | 1.36% | -4.59% | 17.76% | 282.31% |
| Biotech | XBI | 3.04% | 0.10% | 22.24% | 277.33% |
| Homebuilder | XHB | 5.35% | 2.00% | 22.50% | 254.14% |
| Retail | XRT | 2.94% | -1.41% | 32.17% | 292.68% |
Does Kymera Therapeutics outperform its market, is KYMR a Sector Leader?
Yes, over the last 12 months Kymera Therapeutics (KYMR) made 323.63%, while its related Sector, the SPDR S&P Biotech (XBI) made 46.30%.
Over the last 3 months KYMR made 12.14%, while XBI made -3.08%.
Yes, over the last 12 months Kymera Therapeutics (KYMR) made 323.63%, while its related Sector, the SPDR S&P Biotech (XBI) made 46.30%.
Over the last 3 months KYMR made 12.14%, while XBI made -3.08%.
| Period | KYMR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -2.44% | -2.54% | 1.46% |
| 3 Months | 12.14% | -3.08% | 4.69% |
| 12 Months | 323.63% | 46.30% | 42.00% |